Person · CIK 1834161
Mark Eisner
Director at Jade Biosciences and Zura Bio; EVP and Chief Medical Officer at Vir Biotechnology
Earlier: Fibrogen
Sold on Form 4$721K
Noticed on Form 144$1.1M
Bought on Form 4$0
Companies4
Holdings now
As reported after the latest Form 3, 4 or 5 at each company.
How these figures work
Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.
| Company | Security | Held | Shares or units | As of |
|---|---|---|---|---|
| Jade Biosciences JBIO | Stock Option (Right to Buy) exercise $21.81, expires Jun 24, 2036, into Common Stock | Directly | 47,675 | Jun 25, 2026 · Filing · EDGAR |
| Zura Bio ZURA | Share Option (Right to Buy) exercise $3.62, expires Jun 17, 2036, into Class A Ordinary Shares | Directly | 51,000 | Jun 17, 2026 · Filing · EDGAR |
| Vir Biotechnology VIR | Common Stock | Directly | 154,024 | Feb 25, 2026 · Filing · EDGAR |
| Vir Biotechnology VIR | Stock Option (Right to Buy) exercise $7.56, expires Feb 21, 2036, into Common Stock | Directly | 110,000 | Feb 22, 2026 · Filing · EDGAR |
| Fibrogen | Common Stock | Directly | 159,917 | Sep 6, 2023 · Filing · EDGAR |
| Fibrogen | Stock Option (Right to Buy) exercise $22.60, expires Feb 20, 2033, into Common Stock | Directly | 55,000 | Feb 21, 2023 · Filing · EDGAR |
Sold and noticed by quarter
Sold (Form 4) Noticed (Form 144) Bought (Form 4)
Quarterly totals as a table
| Quarter | Sold (Form 4) | Noticed (Form 144) |
|---|---|---|
| Q2 2026 | — | $916K |
| Q1 2026 | $50K | $50K |
| Q3 2025 | $57K | $57K |
| Q2 2023 | $228K | $55K |
| Q1 2023 | $387K | Not machine-readable |
Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.
Planned sales (Form 144) and the sales that followed
Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.
How we match
A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.
| Notice date | Noticed | Planned sale | Outcome | Links |
|---|---|---|---|---|
| Vir Biotechnology VIR · Fidelity Brokerage Services · No 10b5-1 plan stated · 3 notices | ||||
| Apr 30, 2026 | 88,958 · ~$916K | Apr 30, 2026 | Not sold within 90 days | Filing · EDGAR |
| Feb 24, 2026 | 1,616 · ~$15K | Feb 24, 2026 | Sold as noticed Sold 1,616 at $9.53 on Feb 24 · $15K Form 4 | Filing · EDGAR |
| Feb 23, 2026 | 2,089 · ~$16K | Feb 23, 2026 | Sold as noticed Sold 2,089 at $7.45 on Feb 23 · $16K Form 4 | Filing · EDGAR |
| Vir Biotechnology VIR · Fidelity Brokerage Services · 10b5-1 plan adopted Aug 18, 2025 · 1 notice | ||||
| Feb 25, 2026 | 1,889 · ~$19K | Feb 25, 2026 | Sold as noticed Sold 1,889 at $9.82 on Feb 25 · $19K Form 4 | Filing · EDGAR |
| Vir Biotechnology VIR · Morgan Stanley Smith Barney · 10b5-1 plan adopted Aug 5, 2024 · 1 notice | ||||
| Jul 17, 2025 | 3,586 · ~$19K | Jul 17, 2025 | Sold as noticed Sold 3,586 at $5.47 on Jul 17 · $20K Form 4 | Filing · EDGAR |
| Vir Biotechnology VIR · Morgan Stanley Smith Barney · No 10b5-1 plan stated · 1 notice | ||||
| Jul 15, 2025 | 6,796 · ~$37K | Jul 15, 2025 | Sold as noticed Sold 6,796 at $5.47 on Jul 15 · $37K Form 4 | Filing · EDGAR |
| Fibrogen · Etrade Financial · No 10b5-1 plan stated · 2 notices | ||||
| Jun 7, 2023 | 2,042 · ~$35K | Jun 7, 2023 | Sold as noticed Sold 2,042 at $17.04 on Jun 7 · $35K Form 4 | Filing · EDGAR |
| Jun 2, 2023 | 1,090 · ~$21K | Jun 2, 2023 | Sold as noticed Sold 1,090 at $18.83 on Jun 2 · $21K Form 4 | Filing · EDGAR |
| Sales without a matching Form 144 · 5 sales No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt. | ||||
| — | — | — | Notice not machine-readable Fibrogen: Sold 9,182 at $18.78 on Apr 4, 2023 · $172K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Fibrogen: Sold 6,255 at $20.20 on Mar 10, 2023 · $126K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Fibrogen: Sold 3,885 at $20.20 on Mar 10, 2023 · $78K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Fibrogen: Sold 7,363 at $21.16 on Mar 8, 2023 · $156K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Fibrogen: Sold 1,187 at $21.87 on Mar 2, 2023 · $26K | Filing · EDGAR |
Every transaction, by company
Each Form 3, 4 and 5 transaction in plain words, newest first.
How these figures work
Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.
Zura Bio ZURA Director · filings 2026 to 2026
Vir Biotechnology VIR EVP and Chief Medical Officer · filings 2024 to 2026 · sold $106K · $1M noticed on Form 144
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Feb 25, 2026 | Sale under a 10b5-1 plan | −1,889 | $9.82 | $19K | 154,024 direct | Filing · EDGAR |
| Feb 24, 2026 | Sale under a 10b5-1 plan | −1,616 | $9.53 | $15K | 155,913 direct | Filing · EDGAR |
| Feb 23, 2026 | Sale under a 10b5-1 plan | −2,089 | $7.45 | $16K | 157,529 direct | Filing · EDGAR |
| Feb 22, 2026 | Grant or award from the company | +55,000 | 159,618 direct | Filing · EDGAR | ||
| Feb 22, 2026 | Grant or award from the company Stock Option (Right to Buy) | +110,000 | 110,000 direct | Filing · EDGAR | ||
| Jul 17, 2025 | Sale under a 10b5-1 plan | −3,586 | $5.47 | $20K | 104,618 direct | Filing · EDGAR |
| Jul 15, 2025 | Sale under a 10b5-1 plan | −6,796 | $5.47 | $37K | 108,204 direct | Filing · EDGAR |
| Feb 22, 2025 | Grant or award from the company | +40,000 | 115,000 direct | Filing · EDGAR | ||
| Feb 22, 2025 | Grant or award from the company Stock Option (Right to Buy) | +80,000 | 80,000 direct | Filing · EDGAR | ||
| Jul 15, 2024 | Grant or award from the company | +75,000 | 75,000 direct | Filing · EDGAR | ||
| Jul 15, 2024 | Grant or award from the company Stock Option (Right to Buy) | +150,000 | 150,000 direct | Filing · EDGAR |
Fibrogen EVP, Chief Medical Officer · filings 2020 to 2023 · sold $614K · $55K noticed on Form 144
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Sep 6, 2023 | Shares withheld for tax or exercise price | −1,860 | $0.96 | $2K | 159,917 direct | Filing · EDGAR |
| Sep 1, 2023 | Shares withheld for tax or exercise price | −1,085 | $1.06 | $1K | 161,777 direct | Filing · EDGAR |
| Jun 7, 2023 | Open-market or private sale | −2,042 | $17.04 | $35K | 162,862 direct | Filing · EDGAR |
| Jun 2, 2023 | Open-market or private sale | −1,090 | $18.83 | $21K | 164,904 direct | Filing · EDGAR |
| Apr 4, 2023 | Open-market or private sale | −9,182 | $18.78 | $172K | 165,994 direct | Filing · EDGAR |
| Mar 10, 2023 | Open-market or private sale | −3,885 | $20.20 | $78K | 181,431 direct | Filing · EDGAR |
| Mar 10, 2023 | Open-market or private sale | −6,255 | $20.20 | $126K | 175,176 direct | Filing · EDGAR |
| Mar 8, 2023 | Open-market or private sale | −7,363 | $21.16 | $156K | 165,133 direct | Filing · EDGAR |
| Mar 8, 2023 | Grant or award from the company | +7,732 | 172,865 direct | Filing · EDGAR | ||
| Mar 8, 2023 | Grant or award from the company | +12,451 | 185,316 direct | Filing · EDGAR | ||
| Mar 2, 2023 | Open-market or private sale | −1,187 | $21.87 | $26K | 172,496 direct | Filing · EDGAR |
| Feb 21, 2023 | Grant or award from the company | +32,500 | 173,683 direct | Filing · EDGAR | ||
| Feb 21, 2023 | Grant or award from the company Stock Option (Right to Buy) | +55,000 | 55,000 direct | Filing · EDGAR | ||
| Dec 1, 2022 | Shares withheld for tax or exercise price | −1,084 | $15.04 | $16K | 141,183 direct | Filing · EDGAR |
| Sep 30, 2022 | Shares withheld for tax or exercise price | −6,777 | $13.01 | $88K | 142,267 direct | Filing · EDGAR |
| Sep 1, 2022 | Shares withheld for tax or exercise price | −756 | $13.09 | $10K | 149,044 direct | Filing · EDGAR |
| Jun 1, 2022 | Shares withheld for tax or exercise price | −1,141 | $9.61 | $11K | 149,800 direct | Filing · EDGAR |
| Mar 31, 2022 | Shares withheld for tax or exercise price | −6,442 | $12.02 | $77K | 150,941 direct | Filing · EDGAR |
| Mar 1, 2022 | Shares withheld for tax or exercise price | −756 | $13.62 | $10K | 157,383 direct | Filing · EDGAR |
| Feb 14, 2022 | Grant or award from the company | +60,000 | 158,139 direct | Filing · EDGAR | ||
| Feb 14, 2022 | Grant or award from the company Stock Option (Right to Buy) | +100,000 | 100,000 direct | Filing · EDGAR | ||
| Jan 3, 2022 | Shares withheld for tax or exercise price | −7,043 | $14.82 | $104K | 98,139 direct | Filing · EDGAR |
| Dec 1, 2021 | Shares withheld for tax or exercise price | −4,338 | $12.65 | $55K | 105,182 direct | Filing · EDGAR |
| Oct 4, 2021 | Grant or award from the company | +74,520 | 109,520 direct | Filing · EDGAR | ||
| Oct 4, 2021 | Grant or award from the company Stock Option (Right to Buy) | +44,520 | 44,520 direct | Filing · EDGAR | ||
| Dec 1, 2020 | Grant or award from the company | +35,000 | 35,000 direct | Filing · EDGAR | ||
| Dec 1, 2020 | Grant or award from the company Stock Option (Right to Buy) | +80,000 | 80,000 direct | Filing · EDGAR |
All 39 Forms 3, 4, 5 and 144
| Filed | Form | Company | Links |
|---|---|---|---|
| Jun 26, 2026 | Form 4 | Jade Biosciences JBIO | Filing · EDGAR |
| Jun 26, 2026 | Form 3 | Jade Biosciences JBIO | Filing · EDGAR |
| Jun 22, 2026 | Form 4 | Zura Bio ZURA | Filing · EDGAR |
| Apr 30, 2026 | Form 144 | Vir Biotechnology VIR | Filing · EDGAR |
| Feb 26, 2026 | Form 4 | Vir Biotechnology VIR | Filing · EDGAR |
| Feb 25, 2026 | Form 144 | Vir Biotechnology VIR | Filing · EDGAR |
| Feb 24, 2026 | Form 144 | Vir Biotechnology VIR | Filing · EDGAR |
| Feb 24, 2026 | Form 4 | Zura Bio ZURA | Filing · EDGAR |
| Feb 24, 2026 | Form 3 | Zura Bio ZURA | Filing · EDGAR |
| Feb 24, 2026 | Form 4 | Vir Biotechnology VIR | Filing · EDGAR |
| Feb 23, 2026 | Form 144 | Vir Biotechnology VIR | Filing · EDGAR |
| Jul 17, 2025 | Form 144 | Vir Biotechnology VIR | Filing · EDGAR |
| Jul 17, 2025 | Form 4 | Vir Biotechnology VIR | Filing · EDGAR |
| Jul 15, 2025 | Form 144 | Vir Biotechnology VIR | Filing · EDGAR |
| Feb 25, 2025 | Form 4 | Vir Biotechnology VIR | Filing · EDGAR |
| Jul 16, 2024 | Form 4 | Vir Biotechnology VIR | Filing · EDGAR |
| Jun 3, 2024 | Form 3 | Vir Biotechnology VIR | Filing · EDGAR |
| Sep 8, 2023 | Form 4 | Fibrogen | Filing · EDGAR |
| Sep 6, 2023 | Form 4 | Fibrogen | Filing · EDGAR |
| Jun 9, 2023 | Form 4 | Fibrogen | Filing · EDGAR |
| Jun 7, 2023 | Form 144 | Fibrogen | Filing · EDGAR |
| Jun 5, 2023 | Form 4 | Fibrogen | Filing · EDGAR |
| Jun 2, 2023 | Form 144 | Fibrogen | Filing · EDGAR |
| Apr 6, 2023 | Form 4 | Fibrogen | Filing · EDGAR |
| Mar 10, 2023 | Form 4 | Fibrogen | Filing · EDGAR |
| Mar 6, 2023 | Form 4 | Fibrogen | Filing · EDGAR |
| Feb 23, 2023 | Form 4 | Fibrogen | Filing · EDGAR |
| Dec 2, 2022 | Form 4 | Fibrogen | Filing · EDGAR |
| Oct 4, 2022 | Form 4 | Fibrogen | Filing · EDGAR |
| Sep 2, 2022 | Form 4 | Fibrogen | Filing · EDGAR |
| Jun 3, 2022 | Form 4 | Fibrogen | Filing · EDGAR |
| Apr 1, 2022 | Form 4 | Fibrogen | Filing · EDGAR |
| Mar 3, 2022 | Form 4 | Fibrogen | Filing · EDGAR |
| Feb 16, 2022 | Form 4 | Fibrogen | Filing · EDGAR |
| Jan 5, 2022 | Form 4 | Fibrogen | Filing · EDGAR |
| Dec 3, 2021 | Form 4 | Fibrogen | Filing · EDGAR |
| Oct 6, 2021 | Form 4 | Fibrogen | Filing · EDGAR |
| Dec 3, 2020 | Form 4 | Fibrogen | Filing · EDGAR |
| Dec 3, 2020 | Form 3 | Fibrogen | Filing · EDGAR |
Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.
Data on this page was fetched . The filing on SEC.gov is the record.